The New Standard for 340B Compliance in Specialty Pharmacy

For Chief Pharmacy Officers, 340B has never been more critical or more complex. What was once a program primarily focused on eligibility and compliance has expanded into something far broader: a system-wide operational challenge that spans prescribing, pharmacy workflows, payer coordination, and patient access. At the same time, scrutiny is increasing from regulators, manufacturers, and internal compliance teams, placing new pressure on pharmacy leadership to ensure accuracy, transparency, and control across every transaction.

The challenge is not a lack of expertise. Health systems have built sophisticated pharmacy operations and invested heavily in compliance infrastructure. The challenge is that the workflows supporting 340B were never designed for the scale, speed, and complexity of today’s specialty pharmacy environment. Most programs still operate in a retrospective model, where eligibility is assumed at dispense and validated later. Reconciliation, adjustments, and audit preparation follow after the fact, often requiring significant manual effort to resolve discrepancies and confirm compliance.

On paper, this model works. In practice, it introduces friction at every step. Eligibility depends on fragmented data across EHRs, TPAs, wholesalers, and contract pharmacies. Compliance checks occur after medication fulfillment, increasing operational risk. Teams rely on manual reconciliation processes to identify issues that could have been prevented earlier. And perhaps most importantly, pharmacy leaders are often left without a clear, real-time answer to a simple but critical question: was this claim truly compliant?

Even the most advanced programs experience operational variance because of this structure, not because of a lack of rigor, but because of the inherent limitations of retrospective workflows. As specialty pharmacy continues to evolve, with more complex therapies, higher costs, and tighter coordination requirements, this model is becoming increasingly difficult to sustain.

The shift happening now is both subtle and profound. Leading health systems are beginning to move 340B from retrospective validation to prospective orchestration. Instead of asking whether a claim was compliant after the medication has already been dispensed, they are asking whether compliance can be ensured before the prescription ever leaves the point of care. That shift changes the role of 340B entirely. Eligibility is no longer something to confirm later; it becomes something to validate upfront. Compliance is no longer a downstream activity; it becomes embedded directly into the workflow.

When eligibility is validated at the point of order, when provider, location, NDC, and payer rules are checked in real time, and when compliance logic is integrated into prescribing and pharmacy workflows, the entire system begins to operate differently. Exceptions are reduced before they occur. Reconciliation becomes lighter and more predictable. Teams spend less time correcting issues and more time focusing on patient access and care coordination. Most importantly, pharmacy leadership gains confidence that compliance is being maintained continuously, not reconstructed after the fact.

This is the foundation behind LRx360, co-developed by Longitude Rx and powered by Innovaccer’s Gravity platform. Rather than treating 340B as a standalone compliance function, LRx360 brings it into the full specialty prescription journey, connecting every step from the moment a prescription is written through therapy initiation. By unifying data across EHRs, payers, pharmacies, and 340B systems, and embedding intelligence directly into workflows, the platform enables health systems to manage compliance as part of everyday operations rather than as a separate process.

What makes this approach different is not just automation, but alignment. Compliance, workflow, and visibility are brought together into a single system. Pharmacy teams are no longer navigating multiple disconnected tools or reconciling across fragmented data sources. Instead, they operate with a continuous, end-to-end view of the prescription journey, with the ability to intervene early, coordinate effectively, and maintain program integrity with greater clarity.

For Chief Pharmacy Officers, this shift represents more than an operational improvement. It signals a broader change in how specialty pharmacy programs are designed and managed. The role of pharmacy leadership is expanding from overseeing compliance to orchestrating a complex ecosystem that includes clinical care, financial coordination, patient engagement, and regulatory alignment. That requires systems that are not only accurate, but also timely, connected, and intelligent.

When compliance is embedded upstream, the benefits extend beyond reducing administrative burden. Pharmacy teams are able to focus more of their time on supporting patients through complex therapies. Coordination between clinic and pharmacy improves. Visibility into program performance becomes clearer and more actionable. And the organization is better positioned to scale specialty pharmacy services in a way that is both compliant and operationally sustainable.

The future of 340B will not be defined by how well organizations reconcile what has already happened. It will be defined by how effectively they can ensure compliance before it happens. In a healthcare environment that is increasingly real-time, data-driven, and outcome-focused, that distinction matters more than ever.

‍